Choline and Alpha-GPC's as Neuroprotective Agents in Alzheimer's Disease: Mechanisms Involving APOE-ε4-Mediated Neurodegeneration

Alzheimer's disease (AD) remains one of the most prevalent neurodegenerative conditions worldwide, affecting over 3 million Americans annually with no current cure. The APOE-ε4 allele is a significant genetic risk factor for AD, present in 15-25% of the population. This literature review examines emerging evidence suggesting that choline, a phospholipid structural component essential for cellular metabolism, may serve as a potential neuroprotective agent against APOE-ε4-mediated neurodegeneration. We synthesized findings from recent experimental studies, including NIH-supported research demonstrating that choline supplementation addresses lipid metabolism deficits in APOE-4-expressing astrocytes and microglia. Animal model studies revealed that lifelong choline supplementation reduces microglia activation and modulates alpha-7 nicotinic acetylcholine receptor signaling, key mechanisms underlying neuroinflammation in AD pathogenesis. These findings suggest choline functions as a ligand-agonist for sigma-1 receptors, potentially mitigating neuroinflammatory cascades. However, as a comprehensive literature review without original experimental data, these conclusions represent synthesis of existing research rather than definitive clinical evidence. Further preclinical and clinical investigations are necessary to evaluate choline's long-term efficacy as a therapeutic intervention for APOE-ε4-associated neurodegeneration and to establish safe, evidence-based dosing protocols.